CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 29 enrolled
Drug / intervention
Reference Formulation (R) +2 moredrug
Likely dose
LY3337641 (T1) 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03099148
NCT03099148Phase 1Completed
CompareCT.gov

Relative Bioavailability and the Effect of Food on the Bioavailability of LY3337641 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Apr 4, 2017·Updated Oct 17, 2023

In Brief

A Phase 1 clinical trial evaluating Reference Formulation (R), LY3337641 (T1), and 1 other intervention for Healthy. Completed, enrolled 29 participants across 2 sites.

Detailed Summary

The purposes of this study are to determine: * If there are any differences in the amount of LY3337641 in the blood/body when it is taken in different formulations. A total of 3 different formulations of LY3337641 are being tested. * How a high-fat meal affects the amount of LY3337641 in the blood/body. * How safe and well tolerated LY3337641 is. The study has four periods. Individuals will participate in all four periods. Each period will include 4 overnight stays (5 days) in the Clinical Research Unit (CRU). This study is expected to last up to 8 weeks. This includes the initial screening period, the study or dosing period, and the follow up period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 4, 2017
Enrollment StartApr 4, 2017
Primary CompletionMay 31, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.2 years ago

Interventions

Reference Formulation (R)drug

Administered PO

LY3337641 (T1)drug

20 mg PO

LY3337641 (T2)drug

20 mg PO